Investors are showing interest in the development of treatments for NASH (nonalcoholic steatohepatitis), a type of liver disease, as the pipeline for the disease develops in parallel with those R&D efforts. Get a full view of the promising market for NASH in this article from In Vivo.
Author: Amama Sadiq
Published: 25 July 2018
Number of pages:7
NASH (nonalcoholic steatohepatitis, a form of liver disease), affects nearly 25% of the US population, and development of treatments for NASH is growing, even as scientists continue to uncover more about this chronic disease. Explore the outlook for NASH, and understand the factors that are driving research and development in the field, with a comprehensive overview from In Vivo that also explores the importance of partnerships and collaboration for the development of NASH treatments, as well as an update on late-stage trials for the disease.
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.